Clinical and immunologic outcome in patients with human immunodeficiency virus infection, according to virologic efficacy in the year after virus undetectability, during antiretroviral therapy

被引:17
作者
Abgrall, S
Duval, X
Joly, V
Descamps, D
Matheron, S
Costagliola, D
机构
[1] Hop La Pitie Salpetriere, INSERM, EMI 0214, F-75013 Paris, France
[2] Hop Bichat Claude Bernard, F-75877 Paris 18, France
关键词
D O I
10.1086/379070
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
To evaluate factors associated with durable viral suppression (DVS), low viral rebound (virus load of 500-5000 copies/mL), and high viral rebound (virus load above 5000 copies/mL), we studied 3736 patients who achieved an undetectable virus load (i.e., <500 copies/mL) while receiving an initial highly active antiretroviral therapy regimen containing a protease inhibitor ( PI). A total of 2636 patients (71%) had DVS, 387 (10%) had low viral rebound, and 713 (19%) had high viral rebound. Factors associated with DVS were antiretroviral-naive status, choice of PI (indinavir or boosted PI), lower virus load and higher CD4(+) cell count, shorter duration of therapy (<6 months), and larger CD4+ cell increment until an undetectable virus load was attained. These factors ( except for receipt of indinavir) were also associated with low versus high viral rebound. Compared with patients with DVS, patients with high viral rebound were more likely to experience clinical failure (adjusted hazard ratio [aHR], 1.71; 95% confidence interval [CI], 0.97-3.02) and immunologic failure ( aHR, 1.57; 95% CI, 1.34-1.83), and patients with low viral rebound were as likely to experience these types of failure (aHR for clinical failure, 1.18 [95% CI, 0.48-2.92]; aHR for immunologic failure, 1.07 [ 95% CI, 0.87-1.32]), suggesting that a low viral rebound while receiving HAART that contains a PI has no significant consequence on midterm clinical outcome.
引用
收藏
页码:1517 / 1526
页数:10
相关论文
共 26 条
[1]   Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy [J].
Aleman, S ;
Söderbärg, K ;
Visco-Comandini, U ;
Sitbon, G ;
Sönnerborg, A .
AIDS, 2002, 16 (07) :1039-1044
[2]   Positive effects of combined antiretroviral therapy on CD4(+) T cell homeostasis and function in advanced HIV disease [J].
Autran, B ;
Carcelain, G ;
Li, TS ;
Blanc, C ;
Mathez, D ;
Tubiana, R ;
Katlama, C ;
Debre, P ;
Leibowitch, J .
SCIENCE, 1997, 277 (5322) :112-116
[3]   Changes in CD4+ cell count and the risk of opportunistic infection or death after highly active antiretroviral treatment [J].
Chêne, G ;
Binquet, C ;
Moreau, JF ;
Neau, D ;
Pellegrin, I ;
Malvy, D ;
Ceccaldi, J ;
Lacoste, D ;
Dabis, F .
AIDS, 1998, 12 (17) :2313-2320
[4]  
DARMINIO MA, 1998, AIDS, V12, P1631
[5]   Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy [J].
Descamps, D ;
Flandre, P ;
Calvez, V ;
Peytavin, G ;
Meiffredy, V ;
Collin, G ;
Delaugerre, C ;
Robert-Delmas, S ;
Bazin, B ;
Aboulker, JP ;
Pialoux, G ;
Raffi, F ;
Brun-Vézinet, F .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (02) :205-211
[6]  
DUVAL X, 2003, 10 C RETR OPP INF BO
[7]  
elfraissy JF, 2002, PRISE CHARGE THERAPE, P35
[8]  
FAYE A, 1999, 6 C RETR OPP INF CHI, P67
[9]   Drug resistance in patients experiencing early virological failure under a triple combination including indinavir [J].
Gallego, O ;
de Mendoza, C ;
Pérez-Elías, MJ ;
Guardiola, JM ;
Pedreira, J ;
Dalmau, D ;
Gónzalez, J ;
Moreno, A ;
Arribas, JR ;
Rubio, A ;
García-Arata, I ;
Leal, M ;
Domingo, P ;
Soriano, V .
AIDS, 2001, 15 (13) :1701-1706
[10]   Residual low-level viral replication could explain discrepancies between viral load and CD4+ cell response in human immunodeficiency virus-infected patients receiving antiretroviral therapy [J].
García, F ;
Vidal, C ;
Plana, M ;
Cruceta, A ;
Gallart, MT ;
Pumarola, T ;
Miro, JM ;
Gatell, JM .
CLINICAL INFECTIOUS DISEASES, 2000, 30 (02) :392-394